@article{Anant Agrawal_Sanket Saraiya_2022, title={Peripartum Cardiomyopathy}, volume={1}, url={https://pujhsr.paruluniversity.ac.in/index.php/home/article/view/1}, abstractNote={<p>Peripartum Cardiomyopathy (PPCM) is rare form of cardiomyopathy of unknown etiology occurring in late pregnancy or postpartum period. PPCM is assosciated with significant morbidity and mortality in peripartum period. As ACE inhibitors are contraindicated during pregnancy, diuretics and betablockers are main stay of treatment. In postpartum period, PPCM is treated as per guideline directed therapy for heart failure. In many patients with PPCM, LVEF improves after postpartum period but in those, whose LVEF remains depressed has high tendency for recurrence in subsequent pregnancies with increasing mortality. Most common arrhythmias occurring with PPCM are tachyarrythmias and main stay of treatment are beta blockers. Many newer therapies including bromocriptine, pentoxifylline and immunoglobulin are being tried to treat PPCM. Device therapy is seldom required in PPCM and even if recommended, should be waited for atleast 3 to 6 month after diagnosis.</p> <p> </p> <p><strong>Keywords</strong>: Peripartum, Cardiomyopathy, pregnancy, heart failure</p>}, number={1}, journal={Parul University Journal of Health Sciences and Research}, author={Anant Agrawal and Sanket Saraiya}, year={2022}, month={Nov.}, pages={52–60} }